This week’s selection covers UK market access, a major diagnostics transaction, vascular closure, wound care and imaging software. Japan’s developments include reimbursement, growth funding and planned medical-display launches. Dates below identify announcements; regulatory decisions and commercial milestones are stated separately.
1. UK confirms plans for indefinite CE recognition
Announcement date: 2026-10-21
The government intends to legislate for indefinite recognition of EU MDR/IVDR CE-marked devices in Great Britain and align legacy MDD transitions with the EU. UKCA remains available; UK Responsible Person, registration and post-market surveillance requirements remain. This is a confirmed policy direction, not an announcement that the new legislation is already effective.
Primary sources: MHRA announcement / Government consultation outcome
2. QIAGEN agrees to EQT cash takeover proposal
Announcement date: 2026-10-21
QIAGEN and EQT announced an agreement for a €46.50-per-share cash tender offer, valuing the enterprise at approximately €10.8 billion. Completion is expected in mid-2027, subject to tender conditions and regulatory approvals. The acquisition has not closed.
Primary sources: QIAGEN announcement
3. Haemonetics announces PerQseal Elite FDA approval
Announcement date: 2026-10-19
PerQseal Elite received PMA approval for common femoral arteriotomy closure after 14–22F sheath use, sealing openings up to 26F with an absorbable patch. FDA’s decision was October 16; October 19 was the company announcement, not the approval date.
Primary sources: Haemonetics announcement / FDA PMA P250015
4. Solventum announces Restrata–V.A.C. combined-use clearance
Announcement date: 2026-10-19
Solventum announced FDA 510(k) clearance for Restrata synthetic absorbable matrix with specified V.A.C. negative-pressure wound therapy products—not unrestricted use with every V.A.C. product. October 19 is the announcement date; the underlying FDA decision date was not independently verified for this article.
Primary sources: Solventum announcement
5. Elucid announces commercial availability of FFR-IQ
Announcement date: 2026-10-21
Elucid announced commercial availability and 510(k) clearance of FFR-IQ, which estimates fractional flow reserve from coronary CT angiography using vessel geometry and plaque characteristics. It supports assessment of clinically stable patients with suspected coronary disease. FDA’s decision was September 29, not this week.
Primary sources: Elucid announcement / FDA K262015
6. BD Japan reports Rotarex reimbursement and first domestic use
Announcement date: 2026-10-22
BD Japan reported the first domestic use of Rotarex, which combines thrombus fragmentation and aspiration. According to the company, use at Osaka Police Hospital and reimbursement began October 1. The October 22 announcement reports earlier milestones, not a new approval or first procedure this week.
Primary sources: BD Japan announcement
7. iCUREX raises ¥140 million for wound-dressing expansion
Announcement date: 2026-10-22
iCUREX announced ¥100 million in preferred-equity funding plus a ¥40 million Japan Finance Corporation loan. Funds support manufacturing and next-generation development for CHITOSLA CX (キトスラCX) wound dressing. The product was approved in May, reimbursed in July and launched in September; this week’s milestone is financing.
Primary sources: iCUREX announcement
8. EIZO plans two RadiForce monitor launches
Announcement date: 2026-10-22
EIZO plans to launch the 24.1-inch MX247W on December 24, 2026 and the 27-inch 4K MX277W on April 19, 2027. Both include calibration sensors. This is an imaging-display product announcement; both models were still awaiting launch at the time of the announcement.
Primary sources: EIZO announcement
Summary
The week combines market-access policy, diagnostics consolidation and commercialization of combined therapies and imaging software. In Japan, announcements covered the start of reimbursed clinical use, preparations for manufacturing capacity and plans to launch medical imaging displays. Keeping policy, regulatory decisions, announcements and actual launches separate provides a clearer picture of progress.